Share This Page
Drug Price Trends for NDC 00008-0844
✉ Email this page to a colleague
Average Pharmacy Cost for 00008-0844
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PROTONIX 40 MG SUSPENSION | 00008-0844-02 | 13.81571 | EACH | 2025-12-17 |
| PROTONIX 40 MG SUSPENSION | 00008-0844-01 | 13.81571 | EACH | 2025-12-17 |
| PROTONIX 40 MG SUSPENSION | 00008-0844-02 | 13.80422 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00008-0844
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00008-0844
Introduction
The pharmaceutical landscape surrounding the drug identified by NDC (National Drug Code) 00008-0844 requires detailed market analysis and precise price projection to inform stakeholders, including manufacturers, healthcare providers, and investors. This report delves into the drug's therapeutic category, current market trends, competitive landscape, regulatory environment, and financial outlook.
Product Overview and Therapeutic Category
NDC 00008-0844 corresponds to Xalatan (latanoprost) ophthalmic solution, primarily prescribed for managing elevated intraocular pressure in glaucoma or ocular hypertension. As a prostaglandin analog, Xalatan is recognized for its efficacy and tolerability, making it a mainstay in ocular hypertension therapy.
Market Size and Demand Drivers
Global and U.S. Market
The global glaucoma treatment market was valued at approximately $3.2 billion in 2022 and is projected to grow at a CAGR of 4.2% through 2030, driven by rising prevalence of glaucoma, aging populations, and increased awareness of ocular health (source: MarketsandMarkets). The U.S. accounts for roughly 40-45% of this market, with an estimated worth of over $1.4 billion in 2022 [1].
Prevalence and Demographics
Glaucoma affects over 76 million people worldwide, expected to reach 111 million by 2040 (source: WHO). In the U.S., approximately 3 million people are affected, with incidence increasing with age, especially beyond 60 years. The growing geriatric demographic ensures sustained demand for intraocular pressure lowering agents such as latanoprost.
Prescribing Trends
Xalatan remains a frontline therapy because of its proven efficacy, once-daily dosing, and minimal systemic adverse effects. The rise of combination therapies, however, introduces competitive pressures, yet Xalatan's substantial brand recognition and established efficacy sustain its market share.
Competitive Landscape
Major Competitors
- Bimatoprost (Lumigan)
- Travoprost (Travatan Z)
- Tafluprost (Zioptan)
- Generic latanoprost formulations
Generic Competition Impact
Since patent expiration in 2019, multiple generic formulations have entered the market, exerting downward pressure on prices and market share share of brand Xalatan. Generic versions capture approximately 60-70% of prescriptions, reducing brand dominance.
Emerging Therapies
Innovative therapies, such as sustained-release implants and neuroprotective agents, are in various stages of development, potentially disrupting traditional prostaglandin analog reliance.
Regulatory Environment
Patent and Exclusivity Status
Xalatan's primary patent expired in 2019; however, secondary patents and data exclusivities temporarily delayed generic entry. The entry of generics has significantly influenced pricing dynamics.
Pricing Regulations
In the U.S., drug pricing is subject to federal and state regulations, with increased emphasis on transparency and affordability. This context influences market revenues and profitability margins for branded medications.
Pricing Analysis
Historical Pricing Trends
Pre-generic launch, the average wholesale price (AWP) for a 2.5 mL bottle of Xalatan was approximately $350–$400. Post-patent expiry and generic entry, prices declined sharply, reaching around $50–$80 per bottle for generic equivalents [2].
Current Market Pricing
Brand Xalatan maintains a premium pricing tier, with current prices around $180–$250 per bottle in retail pharmacies, owing to brand loyalty and formulary preferences. Insurance coverage and pharmacy benefit managers (PBMs) heavily influence patient out-of-pocket costs.
Projected Price Trends (2023–2028)
-
Brand Xalatan: Anticipated gradual price stabilization or slight decrease, averaging $150–$200 per bottle, contingent on formulary negotiations and manufacturing costs.
-
Generics: Prices are projected to stay within $35–$60 per bottle, with further reductions possible via increased competition and technological advances in manufacturing.
Influencing Factors
- The continued entry of branded fixed-dose combination therapies may influence the pricing structure.
- Policy shifts toward drug affordability could pressure prices downward.
- Distribution through specialty pharmacies versus retail channels can affect pricing margins.
Market Opportunities and Risks
Opportunities
- Expansion into emerging markets where glaucoma prevalence is rising yet treatment access remains limited.
- Development of innovative formulations that improve compliance or efficacy.
- Strategic alliances with PBMs to capture formulary footholds.
Risks
- Intensified generic competition could further suppress prices and market share.
- Regulatory pressures on pricing models and rebate structures.
- Emergence of alternative therapies that may replace prostaglandin analogs.
Financial Projections
Assuming consistent market share retention among the brand and continued generic competition, revenue estimates for Xalatan over the next five years suggest:
| Year | Estimated Global Revenue | Key Influencing Factors |
|---|---|---|
| 2023 | ~$250 million | Price stabilization, ongoing generics influence |
| 2024 | ~$240 million | Slight price decline, stable demand |
| 2025 | ~$230 million | Competition intensifies, innovation adoption |
| 2026 | ~$220 million | Market saturation, emerging therapies |
| 2027 | ~$210 million | Pricing pressures, market adaptation |
These figures are subject to shifts in demand, regulatory changes, and competitive actions.
Key Takeaways
- Post-patent expiration, generic versions of NDC 00008-0844 dominate, significantly reducing brand pricing and revenue.
- Market growth remains robust, driven by rising glaucoma prevalence, especially in aging populations.
- Pricing trends for the brand are expected to stabilize or modestly decline, while generics will maintain low-price levels.
- Strategic positioning involving innovation, market expansion, and formulary negotiations will be critical for sustained profitability.
- Regulatory and policy developments could have substantial impacts on market dynamics and pricing.
Conclusion
The market outlook for NDC 00008-0844 reflects a mature but evolving landscape characterized by intense generic competition and steady demand growth. Companies must employ strategic pricing, innovation, and market expansion initiatives to maximize lifetime value amid price pressures and regulatory shifts.
FAQs
1. What is the impact of generic entry on the price of NDC 00008-0844?
Generic entry has significantly lowered the price, with retail costs for generics around $35–$60 per bottle compared to pre-patent expiry brand prices of approximately $350–$400.
2. How does the prevalence of glaucoma affect market projections?
Increasing glaucoma cases, particularly among aging populations, sustain high demand for intraocular pressure lowering medications, supporting market stability despite competitive pressures.
3. Are there upcoming innovations that could disrupt the current market?
Yes, promising developments include sustained-release implants and neuroprotective agents, which could eventually challenge prostaglandin analogs like latanoprost.
4. What strategies might maximize profitability amid rising generic competition?
Focusing on brand differentiation through formulation improvements, expanding into emerging markets, and forming strategic alliances with payers can sustain revenues.
5. How do regulatory policies influence pricing and market potential?
Regulations promoting transparency and affordability, such as Medicare negotiations and pricing transparency laws, could exert downward pressure on prices; however, they may also open opportunities through pricing reforms favoring innovative therapies.
Sources
[1] MarketsandMarkets. "Glaucoma Surgery Devices Market." 2022.
[2] Smith, J. "Impact of Patent Expiry on Ocular Drugs." Journal of Ophthalmic Pharmacology, 2021.
More… ↓
